Comparison of antiplatelet activity of microencapsulated aspirin 162.5 mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis

British Journal of Clinical Pharmacology

Volumn 48, Issue 1, 1999, Pages 57-62

  Brown, Nigel ^a,c   May, Jane A ^a   Wilcox, Robert G ^a   Allan, Linda M ^b   Wilson, Adrian M ^b   Kiff, Peter S ^b   Heptinstall, Stan ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Searle Medical Department   (United Kingdom)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Antiplatelet activity; Enteric coated aspirin; Low dose aspirin; Microencapsulated aspirin

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CASPAC XL; COLLAGEN; SEROTONIN; THROMBOXANE B2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; ENTERIC COATED TABLET; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROENCAPSULATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; SEROTONIN RELEASE; THROMBOCYTE AGGREGATION;

ARTERIOSCLEROSIS; ASPIRIN; BLOOD PLATELETS; CAPSULES; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; SINGLE-BLIND METHOD; THROMBOXANE B2;

EID: 0033026077     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00947.x     Document Type: Article

References (11)

1. 1 Antiplatelet Trialists Collaboration Collaborative overview of randomised trials of antiplatelet therapy-I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
2. 2 Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-1294.
3. 3 Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995; 310: 827-830.
4. 4 Graham DY, Smith JL. Aspirin and the stomach. Ann Intern Med 1986; 104: 390-398.
5. 5 Gilman AG, Rall TW, Nies AS. Goodman and Gilman's The pharmacological basis of therapeutics. (8th edn.) New York: Pergamon Press 1990.
6. 6 Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348: 1413-1416.
7. 7 Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325: 1137-1141.
8. 8 Fitzgerald GA, Lupinetti M, Charman SA, Charman WN. Presystemic acetylation of platelets by aspirin: Reduction in rate of drug delivery to improve biochemical selectivity for thromboxane A2. J Pharmacol Exp Ther 1991; 259: 1043-1049.
9. 9 Charman WN, Charman SA, Monkhouse DC, et al. Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation. Br J Clin Pharmacol 1993; 36: 470-473.
10. 10 Fox SC, Burgess Wilson M, Heptinstall S, Mitchell JRA. Platelet aggregation in whole blood determined using the Ultra-Flo 100 Platelet Counter. Thromb Haemost 1982; 48 32: 327-329.
11. 11 Heptinstall S, May JA, Glenn JR, Sanderson HM, Dickinson JP, Wilcox RG. Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood. Thromb Haemost 1995; 74: 1310-1315.